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ABSTRACT
Objective. The aim of this paper is to analyze the frequency of the mdr1-1D mutation of the MDR1 
gene in a dog sample of the Uruguayan Cimarron breed with the objective of increasing the knowledge 
of this breed’s genome. Materials and methods. Thirty-six animals of this breed were analyzed. The 
MDR1 gene region, which includes the location where the mutation would be present, was amplified 
by PCR. Results. The mutation was not detected in any of the analyzed Uruguayan Cimarron. 
Conclusions. The lack of described ivermectin intoxication cases in veterinary clinic in this breed is 
explained by the lack of the mutation object of this study. The sequence studied in Cimarron dogs is 
kept compared to other breeds, except Collies and related breeds (Border Collie, Bearded Collie, Old 
English sheepdog).
Key words: Dogs, mutations, pharmacogenetics (Source:CAB).
RESUMEN
Objetivo. El propósito de este trabajo fue analizar la frecuencia de la mutación mdr1-1D del gen MDR1 
en una muestra de perros de raza Cimarrón Uruguayo con el fin de profundizar en el conocimiento 
del genoma del animal. Materiales y métodos. Se analizaron treinta y seis animales de la raza 
mencionada. La región del gen MDR1 que incluiría la mutación se amplificó por PCR. Resultados. En 
los perros cimarrones analizados no se detectó la mutación mencionada. Conclusiones. La ausencia 
de la mutación estudiada explicaría el hecho de que no se hayan descrito casos de intoxicación por 
ivermectina en esta raza. La secuencia en el perro Cimarrón es conservada respecto de otras razas 
caninas, excepto Collie y sus derivadas.
Palabras clave: Farmacogenética, mutaciones, perros (Fuente:CAB).
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INTRODUCTION
Cimarron dogs are the only native canine breed of 
Uruguay. It is believed that they are descendants 
of Mastiffs and Greyhounds (war and hunting 
dogs) introduced by colonizers and conquerors, 
that were used for game hunting and as shepherd 
dogs (1). In 1989 the Cimarron breed was 
officially recognized by the Rural Association of 
Uruguay (ARU) and the Uruguayan Kennel Club 
(KCU). At that moment, the Breeders Society 
of Uruguayan Cimarron dog was created which, 
along with the KCU, made the first official registry 
of the breed. Today, this registry has more than 
6000 inscriptions in the genealogical records of 
the KCU. On February 21, 2006, the World Canine 
Organisation recognized the Uruguayan Cimarron 
as a breed in  primary form, standard FCI nº 353 
/ 10.04.2006 / E (2). At the beginning of 2011 
these animals were recognized definitely as a 
breed. Today, these animals have an important 
function in security and protection, as well as 
in working with cattle and in game hunting (2).
Currently, parasite control is achieved through 
the use of pharmaceutical products. Among 
these, the group of  avermectins has received   
great acceptance due to its wide action spectrum 
both on endoparasites and ectoparasites and its 
high pharmacologic potency (doses are in the 
order of mg/kg). Ivermectin was introduced as 
an antiparasitic drug in 1981. It has had a wide 
diffusion and use in different species of domestic 
animals worldwide. Its use is considered safe 
because its action sites are limited to the central 
nervous system (CNS), and so they are protected 
by the blood-brain barrier. For intoxication to 
take place, doses of about mg/kg of weight are 
needed in most species. The symptomatology 
that appears during intoxication cases is due to 
a larger passage of the drug into the CNS. This 
was demonstrated in affected canines by finding 
high ivermectin concentrations at this level (3-5).
The  MDR1 gene (“multiple drug resistance 
gene”), part of the ABC gene family (“ATP 
binding cassette”), codifies for P glycoprotein. 
This glycoprotein, among other functions, is 
responsible for limiting drug entry into the CNS. 
In Collie related breeds (Border Collie, Bearded 
Collie, English Shepherd, Australian Shepherd, 
Scottish Shepherd) and long-hair Whippet and 
Silken Windhounds, the mdr1-1Δ mutation for this 
gene was described, which produces the a frame-
shift followed by the formation of a stop codon, 
which leads to the formation of a protein that 
completely loses its function (3-6). Homozygote 
animals for this mutation have a phenotype 
sensible to ivermectin, which predisposes them to 
a potentially lethal neurotoxicosis (3-5, 7). In our 
country, in general, it is recommended not to use 
this drug in susceptible breeds. This makes its 
use limited, not being possible to take advantage 
of the benefits of this drug. In addition, there are 
other drugs (corticosteroids,  chemotherapeutic 
agents) used in veterinary clinic that also interact 
with the mdr1-1Δ mutation and cause toxic 
reactions in canines, including heterozygote 
animals (4).
Very little is known about Cimarron dog’s 
genome. The aim of this paper is to analyze the 
frequency of the mdr1-1Δ mutation of the MDR1 
gene in a sample of canines of the Uruguayan 
Cimarron breed with the objective of increasing 
the knowledge of MDR1 locus in this breed.
MATERIALS AND METHODS
Analysed samples. Thirty-six not related, 
Uruguayan Cimarron dogs from different regions 
of Uruguay, were analyzed. Blood samples were 
extracted from the anterobrachial vein or from 
the saphenous in asepsis conditions with EDTA 
anticoagulant.  
DNA isolation. Isoamilic phenol-chloroform-
alcohol and the Chelex 100 DNA extraction 
techniques were used, as they were previously 
described (1, 8). 
PCR amplification. The region of the MDR1 
gene, which would include the mdr1-1Δ mutation 
(Figure 1) was amplified using a couple of primers 
according to Neff et al (4) (amplification program 
used: denaturalization: 95ºC, 4 minutes; 35 
cycles of 95ºC, 1 minute, 56ºC, 30 seconds, 
72ºC, 45 seconds). The amplifications were 
made using the thermocycler Multi Gene II from 
Labnet.
Figure 1. Sequence of a region from MDR1 gene. Bolds: Regions where primers anneal. The deletion is marked. 
Gagliardi - Análisis de la mutación mdr1-1D del fen MDR13482 REVISTA MVZ CÓRDOBA  •  Volumen 18(2)  Mayo - Agosto  2013
Primers:
Forward: GGC TTG ATA GGT TGT ATA TGT TGG TG
Reverse: ATT ATA ACT GGA AAA GTT TTG TTT C
Sample analysis. The analyzed samples were 
sequenced in a sequencer 3730 XL DNA Analyzer 
(AB USA) in Macrogen Inc sequencing service, 
Korea, and the results were read with the BioEdit 
program (free distribution) (9). 
RESULTS
A fragment of 154bp was obtained from the 
PCR amplification. The analysis of this region 
where the mdr1-1Δ mutation should be present 
showed that the studied animals did not have 
it. In figure 2 the obtained sequences for 10 of 
the 36 analyzed Cimarron dogs are shown, along 
with 4 Collie samples, which have the mutation.
DISCUSSION
The mdr1-1Δ mutation is present in several 
canine breeds with different frequencies (1, 3, 
4, 10). 
 
The results found in this work are those expected 
if we consider the fact that Cimarron dogs come 
from breeds of Spanish origin, among which there 
are no Collies (English origin). However, since 
little is known about this breed, as mentioned 
above, it is interesting to discard the presence 
of mdr1-1Δ mutation in the breed. In previous 
studies (4) a frequency of the mdr1-1Δ mutation 
between 4% and 50% has been found in different 
breeds. Considering the variable frequency in 
which this mutation appears in the different 
breeds, we cannot discard the appearance of 
such mutation as the number of Cimarron dogs 
increases (1, 3, 4). On the other side, it should 
be taken into account that it was only in the 
1970`s decade that the recuperation of the breed 
began in Cerro Largo (North-eastern province of 
Uruguay). From this point on, the animals were 
spread to the rest of the country (1), and in 1988 
the Cimarron Breeders Society was founded. 
Before this, these dogs had little breeding 
control, being mainly used to work with cattle (1). 
In rural areas, they could have bred with other 
breeds. The fact of not finding the mutation could 
be considered as proof to discard crossbreeding 
with breeds that do have the mutation. On the 
other hand, due to the frequencies in which the 
mutation was described previously (0.6-54.6%) 
(1, 3, 4, 10) and considering that the number 
of animals sequenced in this work is relatively 
low (N=36), we consider that it is important 
to continue increasing the population sample. 
Another factor to be taken into account and that 
would justify the continuity of this study, is the 
interaction between the mutation analyzed and 
the different drugs used in Veterinary Clinic.
It may be concluded that the lack of described 
ivermectin intoxication cases in veterinary clinic 
in this breed is explained by the absence of 
the mutation analyzed. On the other side, the 
sequence studied in Cimarron dogs is conserved 
compared to other breeds, except Collie and 
related animals.
Figure 2. Sequence of the analyzed region of MDR1 gene. Samples with the mutation are Collie dogs (boxes).3483 Gagliardi - Análisis de la mutación mdr1-1D del fen MDR1
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